- Home
- MIRA vs ACRV Comparison
MIRA vs ACRV Comparison
Compare MIRA & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRA | ACRV |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1M | 61.8M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MIRA | ACRV |
|---|---|---|
| Price | $1.47 | $2.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 135.4K | ★ 3.4M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $1.05 |
| 52 Week High | $2.45 | $8.00 |
Technical Indicators
Market Signals| Indicator | MIRA | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 46.25 |
| Support Level | $1.38 | $1.57 |
| Resistance Level | $1.50 | $2.16 |
| Average True Range (ATR) | 0.05 | 0.32 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 56.63 | 22.61 |
Price Performance
Historical ComparisonAbout MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.